Amgen Stock News

Here we discuss five big pharma/biotech companies - SNY, ABBV, BMY, AMGN and VRTX - with the potential to drive investors' wealth higher in 2022 on the back of strong fundamentals.

Catherine Faddis, Founder and CEO of Grace Capital, joins Worldwide Exchange to discuss her current top stock picks.

Related Stocks: CMCSA , AMGN , UL , BDX , FISV , VEA , AEP , GLD , IWN , T , MRKR , PNW , LGVN ,

Amgen has a long track record of producing market-beating shareholder returns. Its newer drugs and biosimilars offer plenty of promise, and management has maintained aggressive share buybacks.

Since reporting Q4 2021 results and 2022 guidance on Monday, at least six Street firms have boosted their price targets for Amgen.

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

Thursday''s top analyst upgrades and downgrades included Advanced Micro Devices, Amgen, Chipotle Mexican Grill, DuPont, Lyft, MGM Resorts, Newmont, Omnicom, Progressive, TPG and Winnebago.

Specialty Pharmaceutical Market 2022 Covid 19 Impact on Top countries data Industry Trends, Share, Size, Demand, Growth Opportunities, Industry Revenue, Future and Business Analysis by Forecast New York, NY -- ( SBWIRE ) -- 02/09/2022 -- Specialty Pharmaceutical Market 2022-2028 A New Market Study, Titled "Specialty Pharmaceutical Market Upcoming Trends, Growth Drivers and Challenges" has been featured on fusionmarketresearch. Description This global study of the Specialty Pharmaceutical Market offers an overview of the existing market trends, drivers, restrictions, and metrics and also offers a viewpoint for important segments. The report also tracks product and services demand growth forecasts for the market. There is also to the study approach a detailed segmental review. A regional study of the global Specialty Pharmaceutical industry is also carried out in North America, Latin America, Asia-Pacific, Europe, and the Near East & Africa. The report mentions growth parameters in the regional markets along with major players dominating the regional growth.

Las Vegas, USA, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Systemic Lupus Erythematosus Pipeline Insights | Research Report 2022 by DelveInsight Systemic Lupus Erythematosus pipeline involves 70+ key companies continuously working towards developing 70+ Systemic Lupus Erythematosus treatment therapies, as per DelveInsight DelveInsight''s ‘ Systemic Lupus Erythematosus Pipeline Insight 2021'' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Systemic Lupus Erythematosus pipeline domain. Some of the essential takeaways from the Systemic Lupus Erythematosus Pipeline report: DelveInsight''s Systemic Lupus Erythematosus Pipeline analysis depicts a robust space with 70 + active players working to develop 70 + pipeline treatment therapies. Some of the key pharmaceutical companies working to develop potential drug candidates to improve the Systemic Lupus Erythematosus treatment scenario include AstraZeneca, Eli Lilly and Company, UCB Pharma, Hoffmann-La Roche, Biogen, ImmuPharma, Xencor, Bristol Myers Squibb, Kumming Pharmaceuticals, Alpine Immune Sciences, Sanofi, Momenta Pharmaceuticals, Pfizer, Idorsia Pharmaceuticals, Resolve Therapeutics, ILTOO Pharma, Amgen, AbbVie, Novartis, Corestem, Corbus Pharmaceuticals, Viela Bio, Janssen Biotech, Boston Pharmaceuticals, InnoCare Pharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, ACEA therapeutics, Mitsubishi Tanabe Pharma Corporation, Janssen Research & Development, Landos Biopharma, Equillium, Merck Healthcare KGaA, Gilead sciences, I-Mab Biopharma, Biocon Limited, Nektar Therapeutics, Hoffman-La-Roche, Sangamo therapeutics, Araim Pharmaceuticals, Chipscreen Biosciences, AstraZeneca/BenevolentAI, Reistone Biopharma, OMass Therapeutics, and many others.

Here is a look at seven stocks that traded up and seven that traded lower in Wednesday''s premarket session.

Amgen (AMGN) outlines a strategy to grow its business through the end of this decade on the back of strong demand for existing products and potential of novel pipeline candidates targeting diverse ind

Tech stocks got off to a positive start Wednesday morning. The Nasdaq traded up about 1.3%, the S&P 500 was up 1.04% and the Dow traded 0.7% higher shortly after the opening bell.

U.S. stocks posted solid gains on Tuesday as investors??? sentiment got a boost from a batch of robust corporate earnings.

Biotechnology sector-specific exchange traded funds were flat after Amgen (NasdaqGS: AMGN) provided a mixed earnings report but announced that it will return value to investors through greater share b